Advertisement

The Management of Peyronie’s Disease

  • Fabio Castiglione
  • David J. Ralph
  • Giulio Garaffa
Chapter

Abstract

Peyronie’s disease (PD) was first described by Francois de la Peyronie (1678–1747), who reported a series of patients with “rosary beads of scar tissue” causing curvature of the penis. Peyronie’s Disease is an acquired benign fibrotic disorder involving the tunica albuginea (TA) of the corpora cavernosa of the penis leading to the formation of fibrous inelastic plaques [1]. Peyronie’s Disease is believed to occur in the genetically susceptible individuals and is associated with penile curvature, pain and worsening of erectile function. Peyronie’s Disease has an estimated prevalence of 3–9% in adult men and is frequently associated with cardiovascular risk factors including diabetes, hypertension, dyslipidaemia, and low serum testosterone levels [2–5].

References

  1. 1.
    Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, Glina S, Hakim L, Sadeghi-Nejad H, Broderick G. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016;13(6):905–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88:727–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Ralph DJ, Gonzalez-Cavadid N, Mirone V, Perovic S, Sohn M, Usta M, Levine L. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7(7):2359–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Kendirci M, Trost L, Sikka SC, Hellstrom GJ. Diabetes mellitus is associated with severe Peyronie’s disease. BJU Int. 2007;99:383–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie’s disease. J Urol. 2002;68:1075–9.Google Scholar
  6. 6.
    Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol. 1990;144:1376–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5:1985–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med. 2009;6(Suppl 3):353–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Castiglione F, Hedlund P, Van der Aa F, Bivalacqua TJ, Rigatti P, Van Poppel H, Montorsi F, De Ridder D, Albersen M. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol. 2013;63(3):551–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph DJ, Stackl W. Peyronie’s disease. J Sex Med. 2004;1:110–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie’s disease (CME). J Sex Med. 2007;4:1527–38.CrossRefPubMedGoogle Scholar
  12. 12.
    Wessells H, Lue TF, McAninch JW. Penile length in the flaccid and erect states: guidelines for penile augmentation. J Urol. 1996;156(3):995–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie’s disease. Int J Impot Res. 2003;15(Suppl 5):S103–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res. 2002;14:414–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Deveci S, Hopps C, O’Brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of Peyronie’s disease in young men. J Sex Med. 2007;4:485–90.CrossRefPubMedGoogle Scholar
  16. 16.
    Joice GA, Burnett AL. Nonsurgical interventions for Peyronie’s disease: update as of 2016. World J Mens Health. 2016;34(2):65–72.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zarafonetis CJD, Horrax TM. Treatment of Peyronie’s disease with potassium paraaminobenzoate (Potaba). J Urol. 1959;81:770–2.CrossRefPubMedGoogle Scholar
  18. 18.
    Shah PJR, Green NA, Adib RS, et al. A multicentre doubleblind controlled clinical trial of potassium-para-aminobenzoate (Potaba) in Peyronie’s disease. Prog Reprod Biol Med. 1983;9:61–7.Google Scholar
  19. 19.
    Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebocontrolled, randomized study. Eur Urol. 2005;47:530–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Paulis G, Cavallini G, Brancato T, Alvaro R. Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie’s disease). results of a controlled study. Inflamm Allergy Drug Targets. 2013;12(1):61–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Biol Med. 1983;9:41–5.Google Scholar
  22. 22.
    Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-Lcarnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a doubleblind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398–403.CrossRefPubMedGoogle Scholar
  23. 23.
    Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162:2003–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44:291–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12:169–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238–43.CrossRefPubMedGoogle Scholar
  27. 27.
    Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91:522–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3:111–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, Eisenberg ML, Lue TF. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7:215–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35:190–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Dell'Atti L. Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie’s disease. Urol Ann. 2015;7:345–9.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114:898–900.CrossRefPubMedGoogle Scholar
  34. 34.
    Desanctis PN, Furey CA Jr. Steroid injection therapy for Peyronie’s disease: a 10-year summary and review of 38 cases. J Urol. 1967;97:114–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Toksu E. Peyronie’s disease: a method of treatment. J Urol. 1971;105:523–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Furey CA Jr. Peyronie’s disease: treatment by the local injection of meticortelone and hydrocortisone. J Urol. 1957;77:251–66l.CrossRefPubMedGoogle Scholar
  37. 37.
    Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. Betamethasone versus placebo in Peyronie’s disease. Arch Ital Urol Androl. 1998;70:165–8.PubMedGoogle Scholar
  38. 38.
    Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.CrossRefPubMedGoogle Scholar
  39. 39.
    Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12:248–58.CrossRefPubMedGoogle Scholar
  40. 40.
    Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650–6.CrossRefPubMedGoogle Scholar
  41. 41.
    US Food & Drug Administration (FDA). FDA approves drug treatment for Peyronie’s disease [Internet]. Silver Spring, MD: US FDA; 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377849.htm. Accessed 11 Aug 2016Google Scholar
  42. 42.
    Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151:1522–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol. 1997;158:1395–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Levine LA, Goldman K, Greenfield J. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168:621–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176:394–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology. 2006;67:1038–42.CrossRefPubMedGoogle Scholar
  47. 47.
    Fojecki GL, Tiessen S, Osther PJ. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain. World J Urol. 2016;Google Scholar
  48. 48.
    Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10:2815–21.CrossRefPubMedGoogle Scholar
  49. 49.
    Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int J Impot Res. 2016;Google Scholar
  50. 50.
    Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie’s disease. J Urol. 2000;163:95–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Di Stasi S, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol. 2004;171:1605–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J Urol. 2007;177:972–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Li J, Duncan RL, Burr DB, Turner CH. L-Type calcium channels mediate mechanically induced bone formation in vivo. J Bone Miner Res. 2003;18:58–66.CrossRefPubMedGoogle Scholar
  54. 54.
    Alman BA, Greel DA, Ruby LK, et al. Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis (Dupuytren contracture) by mechanical strain. J Orthop Res. 1996;14:722–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Brighton CT, Fisher JRS Jr, Levine SE, et al. The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus. J Bone Joint Surg Am. 1996;78:1337–47.CrossRefPubMedGoogle Scholar
  56. 56.
    Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5:1468–73.CrossRefPubMedGoogle Scholar
  57. 57.
    Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med. 2009;6:559–66.CrossRefGoogle Scholar
  58. 58.
    Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie’s disease. Curr Opin Urol. 2004;6:381–8.CrossRefGoogle Scholar
  59. 59.
    Dimitriou R, Levine LA. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie’s disease. J Urol. 1999;161:1014A.Google Scholar
  60. 60.
    Levine LA, Lenting E. A surgical algorithm for the treatment of Peyronie’s disease. J Urol. 1997;158:2149–52.CrossRefPubMedGoogle Scholar
  61. 61.
    Ralph DJ, Minhas S. The management of Peyronie’s disease. BJU Int. 2004;93:208–15.CrossRefPubMedGoogle Scholar
  62. 62.
    Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol. 1965;93:230–2.CrossRefPubMedGoogle Scholar
  63. 63.
    Ralph DJ, al-Akraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J Urol 1995; 4: 1362–1363.Google Scholar
  64. 64.
    Essed E, Schroeder F. New surgical technique for Peyronie’s disease. Urology. 1985;25:582–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Hauck E, Bschlaipfer T, Diemer T, Manning M, Schroeder-Printzen I, Weidner W. Long term results of Essed-Schroeder plication by the use of non absorbable Goretex sutures for correcting congenital penile curvature. Int J Impot Res. 2002;14(3):146–50.CrossRefPubMedGoogle Scholar
  66. 66.
    Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002;167:2066–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Taylor FL, Levine LA. Surgical correction of Peyronie’s disease using Tunica Albuginea plication or partial plaque excision with pericardial graft: long-term followup. J Sex Med. 2008;5:2221–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol. 1990;143:80–2.CrossRefPubMedGoogle Scholar
  69. 69.
    Dalkin BL, Carter MF. Venogenic impotence following dermal graft repair for Peyronie’s disease. J Urol. 1991;146:849–51.CrossRefPubMedGoogle Scholar
  70. 70.
    Gelbard MK. Relaxing incisions in the correction of penile deformity due to Peyronie’s disease. J Urol. 1995;154:1457–60.CrossRefPubMedGoogle Scholar
  71. 71.
    Mulhall JP, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie’s disease and erectile dysfunction: Functional and satisfaction outcomes. J Sex Med. 2005;2:132–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie’s disease. J Sex Med. 2007;4:1500–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Leungwattanakij S, Bivalacqua TJ, Reddy S, Hellstrom WJ. Long-term follow-up on use of pericardial graft in the surgical management of Peyronie’s disease. Int J Impot Res. 2001;13:183–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Grafts materials in Peyronie’s disease surgery: a comprehensive review. J Sex Med. 2007;4:581–95.CrossRefPubMedGoogle Scholar
  75. 75.
    Brannigan RE, Kim ED, Oyasu R, McVary KT. Comparison of tunica albuginea substitute for the treatment of Peyronie’s disease. J Urol. 1998;159:1064–8.CrossRefPubMedGoogle Scholar
  76. 76.
    El Sakka AI, Lue TF. Venous grafting for the correction of penile curvature in Peyronie’s disease. Curr Opin Urol. 1998;8(6):541–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Kadioglu A, Tfekli A, Usta M, Demirel S, Tallaloglu S. Surgical treatment of Peyronie’s disease with incision and venous patch technique. Int J Impot Res. 1999;11(2):75–81.CrossRefPubMedGoogle Scholar
  78. 78.
    Arena F, Peracchia G, Di Stefano C, Barbieri A, Cortellini P. Peyronie’s disease: incision and dorsal vein grafting combined with contralateral plication in straightening the penis. Scand J Urol Nephrol. 1999;33(3):181–5.CrossRefPubMedGoogle Scholar
  79. 79.
    Akkus E, Ozkara H, Alici B, Demirkesen O, Akaydin A, Hattat H, Solok V. Incision and venous patch graft in the surgical treatment of penile curvature in Peyornie’s disease. Eur Urol. 2001;40(5):531–6.CrossRefPubMedGoogle Scholar
  80. 80.
    Adeniyi A, Goorney SR, Pryor JP, Ralph DJ. The Lue procedure: analysis of the outcome in Peyronie’s disease. BJU Int. 2002;89:404–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie’s disease. J Urol. 2003;170:2359–62.CrossRefPubMedGoogle Scholar
  82. 82.
    Montorsi F, Salonia A, Briganti A, Dehò F, Zanni G, Luigi DP, Rigatti P. Five year follow up of plaque incision and vein grafting for Peyronie’s disease [Abst 1256]. Annual meeting of the American Urological Association; 2004.Google Scholar
  83. 83.
    Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie’s disease. BJU Int. 2005;95:1029–33.CrossRefPubMedGoogle Scholar
  84. 84.
    Shioshvili TJ, Kakonashvili AP. The surgical treatment of Peyronie’s disease: replacement of plaque with free autograft of buccal mucosa. Eur Urol. 2005;48(1):129–33.CrossRefPubMedGoogle Scholar
  85. 85.
    Kalsi J, Cristopher AN, Ralph DJ, Minhas S. Plaque incision and fascia lata grafting in the surgical management of Peyronie’s disease. BJU Int. 2006;98(1):110–4.CrossRefPubMedGoogle Scholar
  86. 86.
    Cormio L, Zucchi A, Lorusso F, Selvaggio O, Fioretti F, Porena M, Carrieri G. Surgical treatment of Peyronie’s disease by plaque incision and grafting with buccal mucosa. Eur Urol. 2009;55(6):1479–65.CrossRefGoogle Scholar
  87. 87.
    Egydio PH, Lucon AM, Arap S. Treatment of Peyronie’s disease by incomplete circumferential incession of the tunica albuginea and plaque with bovine pericardium graft. Urology. 2002;59:570–4.CrossRefPubMedGoogle Scholar
  88. 88.
    Sansalone S, Garaffa G, Djinovic R, Pecoraro S, Silvani M, Barbagli G, Zucchi A, Vespasiani G, Loreto C. Long-term results of the surgical treatment of Peyronie’s disease with the Egydio’s technique: a European multicentre study. Asian J Androl. 2011;13(6):842–6.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Levine LA, Greenfield JM, Estrada CR. Erectile dysfunction following surgical correction of Peyronie’s disease and a pilot study of the use of Sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med. 2007;5:241–7.Google Scholar
  90. 90.
    Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie’s disease. BJU Int. 2011;108(7):1152–6.CrossRefPubMedGoogle Scholar
  91. 91.
    Bonillo MA, Garaffa G, Ralph DJ. Addressing residual penile deformity in the Peyronie’s disease patient during penile implant surgery. Curr Sex Health Rep. 2007;4(4):163–6.CrossRefGoogle Scholar
  92. 92.
    Wilson SK, Carson CC. Surgical straightening with penile prosthesis. In: Levine L, editor. Peyronie’s disease. a guide to clinical management. Totowa, NJ: Humana; 2007. p. 249–58.Google Scholar
  93. 93.
    Wilson SK, Delk JR. A new treatment for Peyronie’s disease: modelling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121–3.CrossRefPubMedGoogle Scholar
  94. 94.
    Wilson SK, Cleves MA, Delk JR II. Long term follow up of treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 2001;165:825–9.CrossRefPubMedGoogle Scholar
  95. 95.
    Kovalczyk JJ, Mulcahy JJ. Penile curvatures and aneurysmal defects with the Ultrex penile prosthesis corrected with the insertion of AMS 700 CX. J Urol. 2001;165:825–9.CrossRefGoogle Scholar
  96. 96.
    Chung E, Solomon M, De Young L, Brock GB. Comparison between AMS 700 CX and coloplast titan inflatable penile prosthesis for Peyronie’s disease treatment and remodelling: clinical outcomes and patients satisfaction. J Sex Med. 2013;10(11):2855–60.CrossRefPubMedGoogle Scholar
  97. 97.
    Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie’s disease. Int J Impot Res. 2000;12:147–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Fabio Castiglione
    • 1
  • David J. Ralph
    • 1
  • Giulio Garaffa
    • 1
  1. 1.Department of Urology, The Institute of UrologyUniversity College London HospitalsLondonUK

Personalised recommendations